Phase 4 N=166 Treatment of Acute Sinusitis
Acute Respiratory Infections · Acute Rhinosinusitis
Primary: SNOT-16 Score (Sino-Nasal Outcomes Test) at Day 3 — 1.12; 1.14 Units on a scale — p=0.83
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=944 Efficacy and Safety of Acetylcysteine for the Treatment of Acute Uncomplicated Rhinosinusitis
Rhinosinusitis
Primary: Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period, Full Analysis Set — -4.8213; -4.7394; -4.7758; -5.0180 Score on a scale
Phase 4 N=179 Clinical Trial of the Treatment of Acute Sinusitis With Standard-dose Versus High-dose Amoxicillin/Clavulanate
Sinusitis
Primary: Subjective Improvement - Day 3 (Rating of "a Lot Better" or "no Symptoms") — 33; 31; 22; 33 Participants
Phase 2 N=43 Anti-Inflammatory Agent in Sinusitis
Nasal Polyps
Primary: TOTAL POLYP SCORE (TPS) — 4.67; 5.24 units on a scale — p=<0.05
Phase 3 N=386 Efficacy and Safety of a Herbal Medicinal Product (Dry Extract BNO 1016) in Patients With Acute Rhinosinusitis
Acute Rhinosinusitis
Primary: Major Symptom Score (MSS) Assessed by the Investigator — 2.38; 3.41 units on a scale
Phase 3 N=25 Oral Versus Topical Antibiotics for Chronic Rhinosinusitis Exacerbations
Chronic Rhinosinusitis
Primary: Change in Rhinosinusitis Disability Index (RSDI) Score — -8.000; -14.82 units on a scale — p=0.505
Phase 3 N=27 Study to Assess the Efficacy and Safety of Potassium Clavulanate/Amoxicillin in Children With Acute Bacterial Rhinosinusitis
Sinusitis, Acute
Primary: Number of Participants With a Clinical Outcome of "Cure" at Test of Cure (TOC: Day 15) — 23; 3; 0 Participants
Phase 4 N=49 Sinuclean's Treatment Of Sinusitis' Symptoms
Sinusitis
Primary: Presence of Mucus in the Paranasal Sinuses (Outcome Measure Percentage of Patients) — 71; 57; 33 percentage of patients — p=<0.05
N/A N=98 Short (5 Days) Versus Long (14 Days) Duration of Antimicrobial Therapy for Acute Bacterial Sinusitis in Children
Sinusitis
Primary: Proportion of Children With Clinical Relapse on Day 10 (Short Course) vs Day 20 (Long Course) — 13; 8; 9; 10 Participants
Phase 3 N=515 Efficacy of Antibiotics in Children With Acute Sinusitis: Which Subgroups Benefit?
Sinusitis · Respiratory Tract Infections
Primary: The Mean Pediatric Rhinosinusitis Symptom Scale (PRSS) Score Over the First 10 Days of Follow-up According to the Presence of Pathogens in the Nasopharynx at Enrollment…
Phase 2 N=741 Dose Finding Study of Fluticasone Furoate Nasal Spray for Uncomplicated Acute Rhinosinusitis
Sinusitis, Acute
Primary: Mean Change From Baseline in the Daily Major Symptom Score (MSS) Over the Entire Treatment Period (Weeks 1-2) — -2.97; -3.36; -3.33 units on a scale — p=0.008
Phase 3 N=374 BAY12-8039: 5 Days for Sinusitis vs Placebo
Sinusitis
Primary: Percentage of Subjects With Clinical Cure (Modified Intent-to-Treat (MITT)) — 78.1; 66.7; 19.2; 33.3 Percentage of subjects — p=0.189
Phase 4 N=40 Duration of Antibiotic Therapy as Part of Maximal Medical Therapy for Chronic Rhinosinusitis
Sinusitis
Primary: Number of Patients Recommended for Sinus Surgery After 3 Weeks of Antibiotic Therapy — 7; 8; 0; 6 Participants
Phase 4 N=53 Effectiveness of Mometasone Nasal Irrigation for Chronic Rhinosinusitis
Chronic Rhinosinusitis (Diagnosis) · Allergic Rhinosinusitis · Chronic Eosinophilic Rhinosinusitis
Primary: Change in Sino-Nasal Outcome Test Scores (SNOT-22) — 23.18; 17.7 score on a scale
Phase 2 N=19 Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis
Rhinosinusitis
Primary: Change of Inflammation of the Nasal Mucosa and Paranasal Sinus — 0; -0.8 score on a scale
N/A N=294 NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
Acute Rhinosinusitis · Recurrent Acute Rhinosinusitis · Chronic Rhinosinusitis
Primary: Change in the Total Score of the Investigator's Symptomatic Severity Assessment (Day 0, Day 14) — -4.37; -3.56 score on a scale
N/A N=40 Comparing the Use of Saline or Saline Plus Gentamycin in Nasal Irrigation to Treat Chronic Sinusitis in Children
Sinusitis
Primary: Change in Computed Tomography (CT) Score After Treatment — -.64; -.63; -.5; -.5 units on a scale
Phase 4 N=68 The Use of Antibiotic Sinonasal Rinse After Sinus Surgery
Chronic Rhinosinusitis
Primary: Quality of Life in Chronic Rhinosinusitis Patients — 23; 21 Units on a scale
Phase 2 N=16 Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis
Sinusitis · Cystic Fibrosis
Primary: Computed Tomography Evidence of Less Sinus Disease — 5.875; 3 units on a scale — p=0.2
N/A N=24 Oral Steroids in Chronic Rhinosinusitis Without Nasal Polyps
Sinusitis
Primary: Sinonasal Outcome Test (SNOT 20) — 50.33; 53.14; 37 Score out of total 100
N/A N=25 Study for the Management of Pediatric Chronic Rhinosinusitis With or Without Balloon Sinuplasty
Rhinitis + Sinusitis, Pediatric Chronic Rhinosinusitis
Primary: Quality of Life (QoL) Outcomes Between Adenoidectomy + Maxillary Sinus Irrigation With or Without the Use of Balloon Dilation or Maxillary Sinus Ostia. — 2.48; 2.5…
N/A N=123 Non-Interventional Open Label Prospective Comparative Observational Study Of Evaluation Of Compliance In The Empiric Treatment With Azithromycin SR Versus Amoxiclav 1000 Mg In Adult Patients With Of Acute Bacterial Maxillary Sinusitis
Maxillary Sinusitis
Primary: Percentage of Participants With Response of Very Convenient or Somewhat Convenient — 100.0; 72.9 Percentage of Participants — p=<0.0001
Phase 3 N=196 Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults
Chronic Sinusitis · Chronic Rhinosinusitis (Diagnosis)
Primary: Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps. — -2.13; -2.06 score on a scale
Phase 3 N=261 Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis
Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps
Primary: Change From Baseline in Facial Pain/Pressure/Fullness on NRS at 2 Hours Post-Dose — -2.70; -2.61 Scores on a scale — p=0.7782
Phase 3 N=223 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device
Nasal Polyps
Primary: Adverse Events — 169 Participants
Phase 2 N=20 Study of Dexpramipexole Chronic Sinusitis With Nasal Polyps and Eosinophilia
Chronic Sinusitis With Nasal Polyps and Eosinophilia
Primary: Ratio to Baseline in Peripheral Blood Eosinophil Counts After 6 Months of Treatment — 0.06 ratio to baseline — p=< 0.001
Phase 2 N=22 The Effectiveness of Topical Silver Colloid in Treating Patients With Recalcitrant Chronic Rhinosinusitis
Rhinosinusitis
Primary: Change in Sino-nasal Outcome Test-22 Score Between Baseline and 6 Weeks, Then 6 Weeks to 12 Weeks. — 59.3; 52.9; 45.4; 51.8 units on a scale
Phase 4 N=118 Pain Control Following Sinus Surgery
Sinusitis · Opioid Use · Opioid Abuse
Primary: Pain Severity — 12.4; 8.5 units on a scale
Phase 3 N=182 Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 2)
Chronic Sinusitis · Chronic Rhinosinusitis (Diagnosis)
Primary: Change From Baseline (CFBL) in the 7-day Average Composite Score of 3 Cardinal Symptoms (3CS) in Participants Without Nasal Polyps — -2.73; -1.61 Change from Baseline in…
Phase 4 N=77 Use of Probiotics as Adjunctive Treatment for Chronic Rhinosinusitis
Chronic Rhinosinusitis
Primary: Mean Reduction in SNOT-20 Scores — 1.8; 5.5 units on a scale — p=0.23